Re: methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Masters
J R
JR
D000283:Administration, Intravesical; D001741:Black or African American; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality; D017326:Clinical Trials, Phase III as Topic; D004351:Drug Resistance; D015251:Epirubicin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009994:Osmolar Concentration; D016032:Randomized Controlled Trials as Topic; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D015251:Epirubicin; D016685:Mitomycin